Anita Y Howe from Springfield, NJ, age 66

Name / Title

Company / Classification

Phones & Addresses

Anita Howe
President

Howe-Lewis International, Inc
Executive Placement Service · Executive Search Services

100 Park Ave, New York, NY 10017
(212)6975000, (212)6976600

Anita Howe
Managerial Secretary

Randolph Township School District
Elementary and Secondary Schools · Elementary/Secondary School

25 Schoolhouse Rd, Dover, NJ 07869
(973)3610808

Resumes

Anita Howe

view source

Work:

Project Linus 2006 - 2010
Chapter Coordinator

Skills:

Microsoft Office
Microsoft Word
Powerpoint
Microsoft Excel
Customer Service

Anita Howe

view source

Anita Howe

view source

Site Lead, Hepatitis C Franchise At Merck

view source

Position:

Site Lead, Hepatitis C Franchise at Merck

Location:

United States

Industry:

Pharmaceuticals

Work:

Merck since 2011
Site Lead, Hepatitis C Franchise
Tibotec Feb 2008 - 2011
Director, Early Drug Development
Wyeth Research Sep 1999 - Feb 2008
Director, Drug Discovery
Schering-Plough Research Institute 1997 - 1999
Senior Scientist, Drug Discovery

Education:

New Jersey Institute of Technology 2003 - 2005
Certificate, Pharmaceutical Management Harvard Medical School 1995 - 1997
Post-Doctoral Fellow, HIV/Vaccine University of Alberta 1989 - 1995
Ph.D., Medical Microbiology

Skills:

Drug Discovery
Pharmaceutical Industry
Drug Development

Us Patents

Combination Therapy Method For Treating Hepatitis C Virus Infection And Pharmaceutical Compositions For Use Therein
view source
US Patent:

20080075695, Mar 27, 2008
Filed:

Aug 23, 2007
Appl. No.:

11/843941
Inventors:

Anita Howe - Paoli PA, US
Stephen Villano - Philadelphia PA, US
International Classification:

A61K 38/21
A61P 31/12
US Classification:

424085500, 424085400, 424085600, 424085700
Abstract:

Combination therapy methods for the treatment of hepatitis C virus infection and associated diseases, by the co-administration of 5-cyclopropyl-2-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methanesulfonyl-amino]-benzofuran-3-carboxylic acid methylamide or a pharmaceutically acceptable salt thereof with natural, recombinant or modified interferon, that effectively inhibit viral replication.

Identification And Characterization Of Hcv Replicon Variants With Reduced Susceptibility To Hcv-796, And Methods Related Thereto
view source
US Patent:

20080182895, Jul 31, 2008
Filed:

Aug 21, 2007
Appl. No.:

11/842312
Inventors:

Anita Y.M. Howe - Paoli PA, US
Rajiv Chopra - Andover MA, US
International Classification:

A61K 31/343
C12Q 1/00
A61P 31/12
US Classification:

514469, 435 4
Abstract:

The present invention provides methods of decreasing the frequency of emergence, decreasing the level of resistance, and delaying the emergence of a treatment-resistant Hepatitis C viral infection, by administering to a subject, either in combination or in series, an inhibitor of the Hepatitis C RNA-dependent RNA polymerase NS5B, e.g., a benzofuran, such as 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide (HCV-796), and at least one additional anti-Hepatitis C agent, e.g., a ribavirin product or an immunomodulator, such as an interferon product. Additionally, the invention relates to methods of monitoring the course of treatment of a Hepatitis C viral infection, methods of monitoring and prognosing a Hepatitis C viral infection, and methods of identifying an individual with a decreased likelihood of responding to an anti-Hepatitis C viral therapy. These methods use the sequence and/or structure of the Hepatitis C RNA-dependent RNA polymerase NS5B to identify the emergence of a treatment-resistant Hepatitis C viral infection, particularly a benzofuran (e.g., HCV-796) treatment-resistant Hepatitis C viral infection.

Novel Hcv Inhibitor Combinations And Methods
view source
US Patent:

20070224167, Sep 27, 2007
Filed:

Feb 9, 2007
Appl. No.:

11/704505
Inventors:

Emillo Emini - Dresher PA, US
Michael Flint - Wayne PA, US
Anita Howe - Paoli PA, US
Bruce Malcolm - Paoli PA, US
Stanley Mullen - Lincoln Park NJ, US
Robert Ralston - Union NJ, US
Xiao Tong - East Brunswick NJ, US
Assignee:

Schering Corporation - Kenilworth NJ
ViroPharma Incorporated - Exton PA
Wyeth - Madison NJ
International Classification:

A61K 38/21
A61K 31/7056
A61K 31/407
A61K 31/343
US Classification:

424085400, 514412000, 514043000, 514469000
Abstract:

Novel hepatitis C virus (“HCV”) inhibitor combinations comprising an HCV protease inhibitor and HCV polymerase inhibitor, and optionally one or more biologically active agents, as well as uses of these combinations as HCV inhibitors and for treating hepatitis C and related disorders are disclosed.